Follow Health Care Reform Insider on Twitter
You are here:  Home  >  Public Health  >  Comparative Effectiveness  >  Current Article

PCORI wades into controversy over effective but high-priced hepatitis drugs

December 18, 2014 

A not-for-profit organization created and funded by the healthcare reform law plans to spend up to $50 million to pay for comparative effectiveness research for hepatitis C treatments just weeks before the third drug in a new breed of treatment regimens is expected to be approved.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>